Navigation Links
Data Published in the New England Journal of Medicine for Vedolizumab, an Investigational New Drug from Takeda for Moderately to Severely Active Ulcerative Colitis and Crohn's Disease
Date:8/21/2013

ocorticoid-free remission was seen in 31.7 percent and 28.8 percent of patients taking oral glucocorticoids at baseline randomized, respectively, to vedolizumab every eight weeks or every four weeks versus 15.9 percent of patients receiving placebo at week 52 (p=0.02, p=0.04, respectively).

The safety population in GEMINI II comprised 1,115 patients for weeks 0-52. The most common adverse events reported in the 814-patient vedolizumab arm (˃8.0 percent) were Crohn's disease exacerbation, arthralgia, pyrexia, nasopharyngitis, headache, nausea and abdominal pain. The most common adverse events reported in the 301-patient placebo arm (greater than or equal to 8.0 percent) were Crohn's disease exacerbation, headache, arthralgia, pyrexia, abdominal pain, nausea, and nasopharyngitis. Five deaths occurred during the study period, four among patients receiving vedolizumab (one death each from Crohn's disease with sepsis, intentional overdose of prescription medication, myocarditis, and septic shock) and one in the placebo group (from bronchopneumonia).

About the GEMINI™ Studies          
Announced in early 2009, the GEMINI Studies™ is a Phase 3 program evaluating the effect of vedolizumab on clinical response and remission (along with effect on mucosal healing in UC), and long-term safety in moderately to severely active CD and UC patients who had failed at least one conventional therapy or a TNFalpha antagonist. The GEMINI program consists of four separate studies – a placebo-controlled induction and maintenance study in patients with UC (GEMINI I), a placebo-controlled induction and maintenance study in patients with CD (GEMINI II), a placebo-controlled induction study in patients with CD (GEMINI III) and an open-label long-term safety study in patients with either CD or UC (GEMINI LTS).

About Crohn's disease and ulcerative colitis
Crohn's disease (CD) and ul
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. 1st Case Report of Using Single-Site Cannulation ECMO to Treat SynCardia Total Artificial Heart Patient Published in Journal of Cardiothoracic Surgery
2. Mechanism for Cardiac Effects of Trevena Angiotensin Receptor Biased Ligands Examined in Published Study
3. Leadership Through Research Collaboration Is Reflected In Articles Published In Alzheimers Association Journal
4. Depression Study Published on BCM-95 Curcumin
5. Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine
6. Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine
7. BioElectronics New Patent Published
8. Benefits of Using Hologics Breast Tomosynthesis Mammography Technology Supported in Published Italian Study
9. Clinical Results for Orameds Oral Diabetes Treatment Published in Peer Reviewed Journal PLOS ONE
10. Study Published in European Radiology Further Supports the Use of Hologics Breast Tomosynthesis in Cancer Screening in Practices Using Double Reads
11. Data on SEEKs Novel Immunotherapy for HIV Published in Virology Journal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014  Hologic, Inc. (NASDAQ: ... , Hologic,s President and Chief Executive Officer, will preside ... October 1, the first day of Breast Cancer Awareness ... Company,s campaign focused on the important benefits of Hologic,s ... the FDA as clinically superior to traditional mammography. ...
(Date:9/30/2014)... , Sept. 30, 2014 Arbor ... Summary Global Markets Direct,s, ,Arbor Pharmaceuticals, ... an overview of the Arbor Pharmaceuticals, LLC.,s pharmaceutical ... comprehensive information on the current therapeutic developmental pipeline ... at various stages, therapeutics assessment by drug target, ...
(Date:9/30/2014)... September 30, 2014 ... the "Glycobiology/Glycomics Market by Product [Enzymes (Glycosyltransferase, Neuraminidase, ... and Reagents], Application (Immunology, Oncology) & by ... published by MarketsandMarkets, provides a detailed overview ... current market trends, and strategies impacting the ...
Breaking Medicine Technology:Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 2Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 3Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4
... 26, 2011 NuMe Health LLC, a biotechnology company ... today announced that it has closed a series A-1 ... chief executive officer.  The $675,000 financing was led by ... a larger series A round. The funds from the ...
... 2011 Reportlinker.com announces that a new ... catalogue: China Cardiac Catheters ... http://www.reportlinker.com/p0575380/China-Cardiac-Catheters-and-Guidewires---Market-Trends-Till-2016.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Surgical_Equipment ... This market report provides vital market data ...
Cached Medicine Technology:NuMe Health Announces Closing of Series A-1 Financing Round 2NuMe Health Announces Closing of Series A-1 Financing Round 3NuMe Health Announces Closing of Series A-1 Financing Round 4NuMe Health Announces Closing of Series A-1 Financing Round 5China Cardiac Catheters and Guidewires - Market Trends Till 2016 2China Cardiac Catheters and Guidewires - Market Trends Till 2016 3
(Date:10/1/2014)... ST. LOUIS, MO (PRWEB) October 01, 2014 ... up for Castlewood Eating Disorder Treatment Center’s first ever charity ... provides grants for people with eating disorders who cannot afford ... Fox Run Golf Club in Eureka, Mo. , The ... time at noon. A reception and award dinner will begin ...
(Date:10/1/2014)... 01, 2014 Beverly Hills licensed Clinical ... is celebrating 20 years of private practice in her ... people to achieve greater joy and fulfillment in their ... warning signs and suggestions for anyone who suspects they ... “Believe it or not, it’s not always easy ...
(Date:10/1/2014)... Innovations announces the upcoming airing of Innovations with ... 20, 2014 at 7:30 a.m. EST/PT via Discovery Channel. ... scenes to learn about Break the Cycle’s comprehensive dating ... help and information Break the Cycle provides to teens ... abuse, how to navigate the legal system, and provides ...
(Date:10/1/2014)... NoteSwift Inc., announced today their new ... and 13.0. NoteSwift is the bridge between the EHR ... and document clinical information at the point of care. ... patient note by more than half – and virtually ... points providers state impedes EHR use according to the ...
(Date:10/1/2014)... Scientists at the University of Western ... immune system proteins has the power to knock out ... of the new study on their website. Click ... in the UWA School of Pathology and Laboratory Medicine ... with mesothelioma with promising results. , “A timed ...
Breaking Medicine News(10 mins):Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3Health News:Innovations to Explore Breakthroughs in Health and Wellness in Upcoming Episode Airing Monday, October 20, 2014 via Discovery Channel 2Health News:NoteSwift Joins Allscripts Developer Program 2Health News:NoteSwift Joins Allscripts Developer Program 3Health News:New Mesothelioma Study Says Mice Cured by Immuntherapy “Cocktail”, Reports Surviving Mesothelioma 2
... 5, 2008--Worldwide, an average 95.4 percent of LASIK patients ... first review of the world body of scientific literature, ... announced today. , With 16.3 million patients having ... clinical study and technological innovation behind it, LASIK is ...
... March 7 The rheumatoid arthritis (RA),treatment market, held ... withdrawal of Vioxx and Bextra, is rebounding due to ... to,treat RA topped $12 billion in 2006 and -- ... over 11% a year through 2011,according to a new ...
... Following Bi-Partisan Senate Letter, asks Lawmakers,to Reject Proposed ... Make,Reform Much More Difficult to Achieve, Letter ... WASHINGTON, March 7 The Council for Quality,Respiratory ... leading home oxygen,therapy providers and manufacturers who provide ...
... chief of developmental neurobiology at the Medical College of ... has received the 2008 Mathilde Solowey Lecture Award in ... for Advanced Education in the Sciences, honors young or ... edge, translational and of broad importance. , Dr. Mei ...
... generated by ... physicians in SEMI program, DETROIT, March 7 ... 2.5 million electronic prescriptions written in,the state of Michigan in 2007 ... Initiative (SEMI) -- helping drive,Michigan to fifth in the nation in ...
... Corgenix Medical Corporation,(OTC Bulletin Board: CONX), a ... be exhibiting its AspirinWorks(R) Test at the,American College ... 2008 conference is being held March 12-14 at ... will be on-hand at booth #807 during ACOFP ...
Cached Medicine News:Health News:LASIK patients report more than 95 percent satisfaction rate worldwide 2Health News:LASIK patients report more than 95 percent satisfaction rate worldwide 3Health News:LASIK patients report more than 95 percent satisfaction rate worldwide 4Health News:In Post-Vioxx Era, Biologics are Reviving the Arthritis Treatment Market 2Health News:Bi-Partisan Members of U.S. House of Representatives Formally Oppose Funding Reductions to Medicare's Home Oxygen Benefit 2Health News:Bi-Partisan Members of U.S. House of Representatives Formally Oppose Funding Reductions to Medicare's Home Oxygen Benefit 3Health News:Dr. Mei receives 2008 Mathilde Solowey Lecture Award in Neurosciences 2Health News:Dr. Mei receives 2008 Mathilde Solowey Lecture Award in Neurosciences 3Health News:Southeast Michigan ePrescribing Initiative (SEMI) Drives Michigan into Top Five ePrescribing States Nationally 2Health News:Southeast Michigan ePrescribing Initiative (SEMI) Drives Michigan into Top Five ePrescribing States Nationally 3Health News:Southeast Michigan ePrescribing Initiative (SEMI) Drives Michigan into Top Five ePrescribing States Nationally 4Health News:Southeast Michigan ePrescribing Initiative (SEMI) Drives Michigan into Top Five ePrescribing States Nationally 5Health News:Southeast Michigan ePrescribing Initiative (SEMI) Drives Michigan into Top Five ePrescribing States Nationally 6Health News:Corgenix to Exhibit AspirinWorks(R) Test at 2008 ACOFP Meeting in Denver 2Health News:Corgenix to Exhibit AspirinWorks(R) Test at 2008 ACOFP Meeting in Denver 3
... Laparoscopic Instruments incorporate a layered design unique ... and monitored to prevent stray electrosurgical burns ... by insulation failure or capacitive coupling; a ... built into all AEM Instruments provides a ...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
Medicine Products: